How and why aztreonam works

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Aztreonam is the first clinically tested monocyclic beta-lactam antibiotic (monobactam).
• Its synthetic structure confers specific activity against aerobic gram-negative bacteria and stability to beta-lactamases.
• It exhibits limited activity against gram-positive and anaerobic bacteria due to poor binding to their penicillin-binding protein (PBP) sites.

Purpose of the Study:

• To evaluate the clinical efficacy and pharmacokinetic properties of aztreonam.
• To characterize its spectrum of activity and mechanism of action against various bacterial pathogens.
• To determine its safety profile, particularly its nonnephrotoxic nature.

Main Methods:

• In vitro susceptibility testing to determine minimum inhibitory concentration (MIC) values against key bacterial strains.
• Pharmacokinetic studies assessing drug distribution, elimination half-life, and serum/tissue concentrations after intravenous and intramuscular administration.
• Evaluation of synergistic effects in combination therapy with aminoglycosides.

Main Results:

• Aztreonam demonstrates high affinity for PBP-3 in aerobic gram-negative bacteria, leading to potent inhibition and killing at low concentrations.
• MIC values are typically below 1 µg/mL for Enterobacteriaceae, Neisseria, and Haemophilus species.
• Comparable MIC values to other antipseudomonal agents against Pseudomonas aeruginosa; synergistic activity observed with aminoglycosides against resistant strains.
• Wide distribution into body tissues and fluids, with an elimination half-life of 1.7 hours.
• Serum clearance is proportional to creatinine clearance, necessitating dosage adjustments in renal impairment.

Conclusions:

• Aztreonam is a highly effective antibiotic against aerobic gram-negative bacteria, with a favorable safety profile.
• Its targeted activity and pharmacokinetic properties support its use in treating infections caused by susceptible pathogens.
• The drug's nonnephrotoxic nature and predictable pharmacokinetics make it a valuable therapeutic option, especially when renal function is compromised.